Amarin/Elan Zelapar
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amarin will submit an NDA for Parkinson's treatment Zelapar (rapid-dissolving selegiline) in the first half of 2002 after acquiring U.S. rights from Elan. Amarin (formerly Ethical Holdings) will also promote Elan's Parkinson's drug Permax (pergolide) with 24 reps